HRP20100065T1 - Derivati azapeptida kao inhibitori hiv proteaze - Google Patents
Derivati azapeptida kao inhibitori hiv proteaze Download PDFInfo
- Publication number
- HRP20100065T1 HRP20100065T1 HR20100065T HRP20100065T HRP20100065T1 HR P20100065 T1 HRP20100065 T1 HR P20100065T1 HR 20100065 T HR20100065 T HR 20100065T HR P20100065 T HRP20100065 T HR P20100065T HR P20100065 T1 HRP20100065 T1 HR P20100065T1
- Authority
- HR
- Croatia
- Prior art keywords
- compound
- efavirenz
- pharmaceutically acceptable
- composition according
- inhibitor
- Prior art date
Links
- 239000004030 hiv protease inhibitor Substances 0.000 title claims 3
- 150000001875 compounds Chemical class 0.000 claims abstract 36
- 150000003839 salts Chemical class 0.000 claims abstract 15
- 229910052739 hydrogen Inorganic materials 0.000 claims abstract 2
- 239000000203 mixture Substances 0.000 claims 15
- XPOQHMRABVBWPR-UHFFFAOYSA-N Efavirenz Natural products O1C(=O)NC2=CC=C(Cl)C=C2C1(C(F)(F)F)C#CC1CC1 XPOQHMRABVBWPR-UHFFFAOYSA-N 0.000 claims 14
- 229960003804 efavirenz Drugs 0.000 claims 14
- XPOQHMRABVBWPR-ZDUSSCGKSA-N efavirenz Chemical compound C([C@]1(C2=CC(Cl)=CC=C2NC(=O)O1)C(F)(F)F)#CC1CC1 XPOQHMRABVBWPR-ZDUSSCGKSA-N 0.000 claims 14
- 239000003814 drug Substances 0.000 claims 11
- 229940124597 therapeutic agent Drugs 0.000 claims 9
- BXZVVICBKDXVGW-NKWVEPMBSA-N Didanosine Chemical compound O1[C@H](CO)CC[C@@H]1N1C(NC=NC2=O)=C2N=C1 BXZVVICBKDXVGW-NKWVEPMBSA-N 0.000 claims 8
- XQSPYNMVSIKCOC-NTSWFWBYSA-N Emtricitabine Chemical compound C1=C(F)C(N)=NC(=O)N1[C@H]1O[C@@H](CO)SC1 XQSPYNMVSIKCOC-NTSWFWBYSA-N 0.000 claims 8
- NCDNCNXCDXHOMX-UHFFFAOYSA-N Ritonavir Natural products C=1C=CC=CC=1CC(NC(=O)OCC=1SC=NC=1)C(O)CC(CC=1C=CC=CC=1)NC(=O)C(C(C)C)NC(=O)N(C)CC1=CSC(C(C)C)=N1 NCDNCNXCDXHOMX-UHFFFAOYSA-N 0.000 claims 8
- 229960004748 abacavir Drugs 0.000 claims 8
- MCGSCOLBFJQGHM-SCZZXKLOSA-N abacavir Chemical compound C=12N=CN([C@H]3C=C[C@@H](CO)C3)C2=NC(N)=NC=1NC1CC1 MCGSCOLBFJQGHM-SCZZXKLOSA-N 0.000 claims 8
- 229960002656 didanosine Drugs 0.000 claims 8
- 229960000366 emtricitabine Drugs 0.000 claims 8
- 229960001627 lamivudine Drugs 0.000 claims 8
- JTEGQNOMFQHVDC-NKWVEPMBSA-N lamivudine Chemical compound O=C1N=C(N)C=CN1[C@H]1O[C@@H](CO)SC1 JTEGQNOMFQHVDC-NKWVEPMBSA-N 0.000 claims 8
- 229960000311 ritonavir Drugs 0.000 claims 8
- NCDNCNXCDXHOMX-XGKFQTDJSA-N ritonavir Chemical group N([C@@H](C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC=1C=CC=CC=1)NC(=O)OCC=1SC=NC=1)CC=1C=CC=CC=1)C(=O)N(C)CC1=CSC(C(C)C)=N1 NCDNCNXCDXHOMX-XGKFQTDJSA-N 0.000 claims 8
- 229960001355 tenofovir disoproxil Drugs 0.000 claims 8
- JFVZFKDSXNQEJW-CQSZACIVSA-N tenofovir disoproxil Chemical compound N1=CN=C2N(C[C@@H](C)OCP(=O)(OCOC(=O)OC(C)C)OCOC(=O)OC(C)C)C=NC2=C1N JFVZFKDSXNQEJW-CQSZACIVSA-N 0.000 claims 8
- 229960002555 zidovudine Drugs 0.000 claims 8
- HBOMLICNUCNMMY-XLPZGREQSA-N zidovudine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](N=[N+]=[N-])C1 HBOMLICNUCNMMY-XLPZGREQSA-N 0.000 claims 8
- 239000003112 inhibitor Substances 0.000 claims 6
- 229960004742 raltegravir Drugs 0.000 claims 6
- CZFFBEXEKNGXKS-UHFFFAOYSA-N raltegravir Chemical compound O1C(C)=NN=C1C(=O)NC(C)(C)C1=NC(C(=O)NCC=2C=CC(F)=CC=2)=C(O)C(=O)N1C CZFFBEXEKNGXKS-UHFFFAOYSA-N 0.000 claims 5
- 239000003795 chemical substances by application Substances 0.000 claims 4
- NQDJXKOVJZTUJA-UHFFFAOYSA-N nevirapine Chemical compound C12=NC=CC=C2C(=O)NC=2C(C)=CC=NC=2N1C1CC1 NQDJXKOVJZTUJA-UHFFFAOYSA-N 0.000 claims 4
- IRBAWVGZNJIROV-SFHVURJKSA-N 9-(2-cyclopropylethynyl)-2-[[(2s)-1,4-dioxan-2-yl]methoxy]-6,7-dihydropyrimido[6,1-a]isoquinolin-4-one Chemical compound C1=C2C3=CC=C(C#CC4CC4)C=C3CCN2C(=O)N=C1OC[C@@H]1COCCO1 IRBAWVGZNJIROV-SFHVURJKSA-N 0.000 claims 3
- GSDQYSSLIKJJOG-UHFFFAOYSA-N 4-chloro-2-(3-chloroanilino)benzoic acid Chemical compound OC(=O)C1=CC=C(Cl)C=C1NC1=CC=CC(Cl)=C1 GSDQYSSLIKJJOG-UHFFFAOYSA-N 0.000 claims 2
- 208000031886 HIV Infections Diseases 0.000 claims 2
- 208000037357 HIV infectious disease Diseases 0.000 claims 2
- 229940122440 HIV protease inhibitor Drugs 0.000 claims 2
- KJHKTHWMRKYKJE-SUGCFTRWSA-N Kaletra Chemical compound N1([C@@H](C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC=2C=CC=CC=2)NC(=O)COC=2C(=CC=CC=2C)C)CC=2C=CC=CC=2)CCCNC1=O KJHKTHWMRKYKJE-SUGCFTRWSA-N 0.000 claims 2
- XNKLLVCARDGLGL-JGVFFNPUSA-N Stavudine Chemical compound O=C1NC(=O)C(C)=CN1[C@H]1C=C[C@@H](CO)O1 XNKLLVCARDGLGL-JGVFFNPUSA-N 0.000 claims 2
- 241000700605 Viruses Species 0.000 claims 2
- 229960001830 amprenavir Drugs 0.000 claims 2
- YMARZQAQMVYCKC-OEMFJLHTSA-N amprenavir Chemical compound C([C@@H]([C@H](O)CN(CC(C)C)S(=O)(=O)C=1C=CC(N)=CC=1)NC(=O)O[C@@H]1COCC1)C1=CC=CC=C1 YMARZQAQMVYCKC-OEMFJLHTSA-N 0.000 claims 2
- 230000000798 anti-retroviral effect Effects 0.000 claims 2
- 229960005107 darunavir Drugs 0.000 claims 2
- CJBJHOAVZSMMDJ-HEXNFIEUSA-N darunavir Chemical compound C([C@@H]([C@H](O)CN(CC(C)C)S(=O)(=O)C=1C=CC(N)=CC=1)NC(=O)O[C@@H]1[C@@H]2CCO[C@@H]2OC1)C1=CC=CC=C1 CJBJHOAVZSMMDJ-HEXNFIEUSA-N 0.000 claims 2
- 229960003142 fosamprenavir Drugs 0.000 claims 2
- MLBVMOWEQCZNCC-OEMFJLHTSA-N fosamprenavir Chemical compound C([C@@H]([C@H](OP(O)(O)=O)CN(CC(C)C)S(=O)(=O)C=1C=CC(N)=CC=1)NC(=O)O[C@@H]1COCC1)C1=CC=CC=C1 MLBVMOWEQCZNCC-OEMFJLHTSA-N 0.000 claims 2
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 claims 2
- 229940124524 integrase inhibitor Drugs 0.000 claims 2
- 239000002850 integrase inhibitor Substances 0.000 claims 2
- 229960004525 lopinavir Drugs 0.000 claims 2
- 229960004710 maraviroc Drugs 0.000 claims 2
- GSNHKUDZZFZSJB-QYOOZWMWSA-N maraviroc Chemical compound CC(C)C1=NN=C(C)N1[C@@H]1C[C@H](N2CC[C@H](NC(=O)C3CCC(F)(F)CC3)C=3C=CC=CC=3)CC[C@H]2C1 GSNHKUDZZFZSJB-QYOOZWMWSA-N 0.000 claims 2
- 229960005230 nelfinavir mesylate Drugs 0.000 claims 2
- NQHXCOAXSHGTIA-SKXNDZRYSA-N nelfinavir mesylate Chemical compound CS(O)(=O)=O.CC1=C(O)C=CC=C1C(=O)N[C@H]([C@H](O)CN1[C@@H](C[C@@H]2CCCC[C@@H]2C1)C(=O)NC(C)(C)C)CSC1=CC=CC=C1 NQHXCOAXSHGTIA-SKXNDZRYSA-N 0.000 claims 2
- 229960000689 nevirapine Drugs 0.000 claims 2
- 229940042402 non-nucleoside reverse transcriptase inhibitor Drugs 0.000 claims 2
- 239000002726 nonnucleoside reverse transcriptase inhibitor Substances 0.000 claims 2
- 229940042404 nucleoside and nucleotide reverse transcriptase inhibitor Drugs 0.000 claims 2
- 229960001852 saquinavir Drugs 0.000 claims 2
- QWAXKHKRTORLEM-UGJKXSETSA-N saquinavir Chemical compound C([C@@H]([C@H](O)CN1C[C@H]2CCCC[C@H]2C[C@H]1C(=O)NC(C)(C)C)NC(=O)[C@H](CC(N)=O)NC(=O)C=1N=C2C=CC=CC2=CC=1)C1=CC=CC=C1 QWAXKHKRTORLEM-UGJKXSETSA-N 0.000 claims 2
- 229960001203 stavudine Drugs 0.000 claims 2
- 230000029302 virus maturation Effects 0.000 claims 2
- MGWQOOSAUWCOOU-UHFFFAOYSA-N 1-(3-fluorophenyl)pyrrole-2-carbaldehyde Chemical compound FC1=CC=CC(N2C(=CC=C2)C=O)=C1 MGWQOOSAUWCOOU-UHFFFAOYSA-N 0.000 claims 1
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 claims 1
- 230000001413 cellular effect Effects 0.000 claims 1
- 229910052805 deuterium Inorganic materials 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 230000000155 isotopic effect Effects 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 229960003490 raltegravir potassium Drugs 0.000 claims 1
- QAOWNCQODCNURD-UHFFFAOYSA-L sulfate group Chemical group S(=O)(=O)([O-])[O-] QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/36—Radicals substituted by singly-bound nitrogen atoms
- C07D213/42—Radicals substituted by singly-bound nitrogen atoms having hetero atoms attached to the substituent nitrogen atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
- C07F9/576—Six-membered rings
- C07F9/58—Pyridine rings
Abstract
Spoj formule Ib:ili njegova farmaceutski prihvatljiva sol, gdje se R1a i R1b, neovisno jedan o drugom, biraju od -CD3 i CH3;R3 se bira od -C(CD3)3 i -C(CH3)3; i gdje suY1a i Y1b isti i biraju se od H i D. Patent sadrži još 21 patentni zahtjev.
Claims (22)
1. Spoj formule Ib:
[image]
ili njegova farmaceutski prihvatljiva sol, gdje
se R1a i R1b, neovisno jedan o drugom, biraju od –CD3 i CH3;
R3 se bira od –C(CD3)3 i –C(CH3)3; i gdje su
Y1a i Y1b isti i biraju se od H i D.
2. Spoj prema zahtjevu 1, gdje se spoj bira od
[image]
Spoj 122;
[image]
Spoj 114;
[image]
Spoj 106;
[image]
Spoj 104;
[image]
Spoj 120;
i
[image]
Spoj 123
ili farmaceutski prihvatljive soli bilo kojeg od naprijed navedenih spojeva.
3. Spoj prema zahtjevu 2, gdje se spoj bira od spoja 114, spoja 120, spoja 122 i spoja 131 ili farmaceutski prihvatljive soli bilo kojeg od naprijed navedenih spojeva.
4. Spoj prema zahtjevu 2, gdje je spoj spoj 120 ili njegova farmaceutski prihvatljiva sol.
5. Spoj prema bilo kojem od zahtjeva 1 do 4, gdje je farmaceutski prihvatljiva sol sulfat.
6. Spoj prema bilo kojem od zahtjeva 1 do 5, gdje je bilo koji atom, koji nije označen kao deuterij, prisutan s njegovom prirodnom izotopskom zastupljenošću.
7. Farmaceutska kompozicija koja se sastoji od spoja prema jednom od zahtjeva 1 do 6 i jednog farmaceutski prihvatljivog nosača.
8. Kompozicija prema zahtjevu 7, gdje se spoj bira od spoja 131, spoja 122, spoja 114, spoja 106, spoja 104, spoja 120 i spoja 123 ili farmaceutski prihvatljive soli bilo kojeg od naprijed navedenih spojeva.
9. Kompozicija prema zahtjevu 7 ili zahtjevu 8, koja uz to sadrži i drugo terapeutsko sredstvo.
10. Kompozicija prema zahtjevu 7 ili zahtjevu 8, koja dodatno sadrži drugo terapeutsko sredstvo koje se bira od drugog inhibitora HIV proteaze, nenukleozidnog inhibitora reverzne transkriptaze, nukleozid-nog/nukleotidnog inhibitora reverzne transkriptaze, inhibitora ulaza virusa, inhibitora integraze, antiretroviralnog imunološkog sredstva, inhibitora sazrijevanja virusa, staničnog inhibitora, ili od kombinacija dva ili više gore navedenih.
11. Kompozicija prema zahtjevu 10, gdje se drugo terapeutsko sredstvo bira od ritonavira, efavirenca, didanozina, tenofovir-disoproksila, nelfinavir mesilata, amprenavira, kalij-raltegravira, sakvinavira, lopinavira, nevirapina, emtricitabina, abakavira, lamivudina, zidovudina, maraviroka, stavudina, darunavira, fosamprenavira, vicrivirica, farmaceutski prihvatljive soli bilo kojeg od gore navedenih ili njihove kombinacije.
12. Kompozicija prema zahtjevu 11, gdje se drugo terapeutsko sredstvo bira od ritonavira, efavirenca, didanozina, raltegravira, tenofovir dizoproksila, lamivudina, abakavira, zidovudina, emtricitabina, efavirenca, farmaceutski prihvatljive soli bilo kojeg od gore navedenih i njihovih kombinacija.
13. Kompozicija prema zahtjevu 12, koja sadrži dva do tri dodatna druga tera-peutska sredstva koja se, neovisno jedno o drugom, biraju od ritonavira, efavirenca, didanozina, raltegravira, tenofovir dizoproksila, lamivudina, abakavira, zidovudina, emtricitabina, efavirenca i farmaceutski prihvatljive soli bilo kojeg od naprijed navedenih.
14. Kompozicija prema zahtjevu 13, koja sadrži dva dodatna druga sredstva koja se, naovisno jedan o drugom, biraju od ritonavira, efavirenca, didanozina, raltegravira, tenofovir dizoproksila, lamivudina, abakavira, zi-dovudina, emtricitabina, efavirenca i farmaceutski prihvatljive soli bilo kojeg od naprijed navedenih.
15. Spoj prema jednom od zahtjeva 1 do 6 ili kompozicija prema jednom od zahtjeva 7 do 14 za upotrebu u liječenju HIV infekcije kod pacijenta.
16. Spoj ili kompozicija prema zahtjevu 15 za davanje s drugim terapeutskim sredstvom koje se bira od drugog inhibitora HIV proteaze, nenukleozidnog inhibitora reverzne transkriptaze, nukleozidnog/nukleotidnog inhibitora reverzne transkriptaze, inhibitora ulaska virusa, inhibitora integraze, antiretroviralnog imunološkog sredstva, inhibitora sazrijevanja virusa, staničnog inhibitora, ili kombinacija dva ili više gore navedenih.
17. Spoj ili kompozicija prema zahtjevu 16, gdje se drugo terapeutsko sredstvo bira od ritonavira, efavirenca, didanozina, tenofovir dizoproksila, nelfinavir mesilata, amprenavira, kalij raltegravira, sakvinavira, lopinavira, nevirapina, emtricitabina, abakavira, lamivudina, zidovudina, maraviroka, stavudina, darunavira, fosamprenavira, vicriviroca, farmaceutski prihvatljive soli bilo kojeg od naprijed navedenih i njihovih kombinacija.
18. Spoj ili kompozicija prema zahtjevu 17, gdje se drugo terapeutsko sredstvo bira od ritonavira, efavirenca, didanozina, ralteravira, tenofovir dizoproksila, lamivudina, abakavira, zidovudina, emtricitabina, efavirenca, farmaceutski prihvatljive soli bilo kojeg od naprijed navedenih i njihovih kombinacija.
19. Spoj ili kompozicija prema zahtjevu 15 za davanje s dva do tri dodatna druga terapeutska sredstva koja se, neovisno jedan o drugom, biraju od ritonavira, efavirenca, didanozina, raltegravira, tenofovir dizoproksila, lamivudina, abakavira, zidovudina, emtricitabina, efavirenca i farmaceutski prihvatljive soli bilo kojeg od gore navedenih.
20. Spoj ili kompozicija prema zahtjevu 15 za davanje s dva dodatna druga sredstva koja se, neovisno jedan o drugom, biraju od ritonavira, efavirenca, didanozina, raltegravira, tenofovir dizoproksila, lamivudina, abakavira, zidovudina, emtricitabina, efavirenca i farmaceutski prihvatljive soli bilo kog od naprijed navedenih.
21. Spoj prema bilo kojem od zahtjeva 1 do 6 ili kompozicija prema bilo kojem od zahtjeva 7 do 14 za upotrebu u medicini.
22. Upotreba spoja prema bilo kojem od zahtjeva 1 do 6 ili kompozicije pre-ma bilo kojem od zahtjeva 7 do 14 u proizvodnji lijeka za liječenje HIV-infekcije kod pacijenta.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US93420107P | 2007-06-12 | 2007-06-12 | |
US6762708P | 2008-02-29 | 2008-02-29 |
Publications (1)
Publication Number | Publication Date |
---|---|
HRP20100065T1 true HRP20100065T1 (hr) | 2010-03-31 |
Family
ID=39730784
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HR20100065T HRP20100065T1 (hr) | 2007-06-12 | 2010-02-03 | Derivati azapeptida kao inhibitori hiv proteaze |
Country Status (26)
Country | Link |
---|---|
US (4) | US20090036357A1 (hr) |
EP (3) | EP2003120B9 (hr) |
JP (1) | JP2010529196A (hr) |
KR (2) | KR101185899B1 (hr) |
CN (2) | CN101711237B (hr) |
AR (1) | AR066972A1 (hr) |
AT (2) | ATE536343T1 (hr) |
AU (1) | AU2008267048C1 (hr) |
BR (2) | BRPI0823520A2 (hr) |
CA (1) | CA2692028C (hr) |
CO (1) | CO6241121A2 (hr) |
CY (1) | CY1109766T1 (hr) |
DE (1) | DE602008000255D1 (hr) |
DK (1) | DK2003120T3 (hr) |
ES (3) | ES2356334T3 (hr) |
HK (2) | HK1127345A1 (hr) |
HR (1) | HRP20100065T1 (hr) |
MX (1) | MX2009013565A (hr) |
PL (1) | PL2003120T3 (hr) |
PT (1) | PT2003120E (hr) |
RS (1) | RS51226B (hr) |
RU (2) | RU2448958C2 (hr) |
SI (1) | SI2003120T1 (hr) |
TW (1) | TW200908970A (hr) |
WO (1) | WO2008156632A1 (hr) |
ZA (1) | ZA200909079B (hr) |
Families Citing this family (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TW200835693A (en) * | 2007-02-23 | 2008-09-01 | Auspex Pharmaceuticals Inc | Preparation and utility of non-nucleoside reverse transcriptase inhibitors |
AU2008267048C1 (en) | 2007-06-12 | 2013-01-17 | Concert Pharmaceuticals, Inc. | Azapeptide derivatives |
ES2574988T3 (es) * | 2008-10-06 | 2016-06-23 | Yissum Research Development Company Of The Herbrew University Of Jerusalem Ltd. | Péptidos derivados de estimulantes de la VIH-1 integrasa que interfieren con la proteína Rev-integrasa |
WO2010132663A1 (en) * | 2009-05-13 | 2010-11-18 | Concert Pharmaceticals, Inc. | Pegylated azapeptide derivatives as hiv protease inhibitors |
WO2010135424A1 (en) * | 2009-05-19 | 2010-11-25 | Glaxosmithkline Llc | Chemical compounds |
KR101798430B1 (ko) | 2009-12-21 | 2017-11-16 | 얀센 사이언시즈 아일랜드 유씨 | 활성 화합물의 서방출을 위한 분해 및 제거가능한 임플란트 |
WO2011080562A1 (en) | 2009-12-29 | 2011-07-07 | Hetero Research Foundation | Novel aza-peptides containing 2,2-disubstituted cyclobutyl and/or substituted alkoxy benzyl derivatives as antivirals |
ME03375B (me) | 2011-06-20 | 2020-01-20 | H Lundbeck As | Deuterizovani 1-piperazin0-3-fenil indani za tretiranje šizofrenije |
CN106543073A (zh) * | 2015-09-17 | 2017-03-29 | 宁波杰尔盛化工有限公司 | 2-[4-(2-吡啶基)苄基]-肼羧酸叔丁酯的制备方法 |
CN108367008B (zh) * | 2015-12-02 | 2021-04-30 | 默沙东公司 | 包含多拉韦林、富马酸替诺福韦二吡呋酯和拉米夫定的药物组合物 |
JOP20180009A1 (ar) | 2017-02-06 | 2019-01-30 | Gilead Sciences Inc | مركبات مثبط فيروس hiv |
WO2019025250A1 (en) | 2017-08-04 | 2019-02-07 | Basf Se | SUBSTITUTED TRIFLUOROMETHYLOXADIAZOLES FOR COMBATING PHYTOPATHOGENIC FUNGI |
MA53010A (fr) | 2018-06-29 | 2021-05-05 | Incyte Corp | Formulations d'un inhibiteur de axl/mer |
TWI829205B (zh) | 2018-07-30 | 2024-01-11 | 美商基利科學股份有限公司 | 抗hiv化合物 |
Family Cites Families (36)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA1314875C (en) | 1985-05-15 | 1993-03-23 | George Walter Koszalka | Therapeutic nucleosides |
GB8815265D0 (en) | 1988-06-27 | 1988-08-03 | Wellcome Found | Therapeutic nucleosides |
US5539122A (en) | 1989-05-23 | 1996-07-23 | Abbott Laboratories | Retroviral protease inhibiting compounds |
US5304121A (en) | 1990-12-28 | 1994-04-19 | Boston Scientific Corporation | Drug delivery system making use of a hydrogel polymer coating |
GB9009861D0 (en) | 1990-05-02 | 1990-06-27 | Glaxo Group Ltd | Chemical compounds |
DK0727419T3 (da) | 1992-12-29 | 2002-06-10 | Abbott Lab | Mellemprodukter til fremstilling af forbindelser, som inhiberer retroviral protease |
US5716981A (en) | 1993-07-19 | 1998-02-10 | Angiogenesis Technologies, Inc. | Anti-angiogenic compositions and methods of use |
DE69535592T2 (de) | 1994-03-25 | 2008-06-12 | Isotechnika, Inc., Edmonton | Verbesserung der effektivität von arzneimitteln duren deuterierung |
US6221335B1 (en) | 1994-03-25 | 2001-04-24 | Isotechnika, Inc. | Method of using deuterated calcium channel blockers |
US6099562A (en) | 1996-06-13 | 2000-08-08 | Schneider (Usa) Inc. | Drug coating with topcoat |
TW409125B (en) * | 1996-04-22 | 2000-10-21 | Novartis Ag | Antivirally active heterocyclic azahexane derivatives |
US5849911A (en) | 1996-04-22 | 1998-12-15 | Novartis Finance Corporation | Antivirally active heterocyclic azahexane derivatives |
WO1997046514A1 (en) | 1996-05-31 | 1997-12-11 | Novartis Ag | Process for the preparation of hydrazine derivatives useful as intermediates for the preparation of peptide analogues |
US6087383A (en) * | 1998-01-20 | 2000-07-11 | Bristol-Myers Squibb Company | Bisulfate salt of HIV protease inhibitor |
US6440710B1 (en) | 1998-12-10 | 2002-08-27 | The Scripps Research Institute | Antibody-catalyzed deuteration, tritiation, dedeuteration or detritiation of carbonyl compounds |
GB9914821D0 (en) | 1999-06-24 | 1999-08-25 | Glaxo Group Ltd | Compounds |
GB9925962D0 (en) | 1999-11-02 | 1999-12-29 | Novartis Ag | Organic compounds |
DK1104760T3 (da) | 1999-12-03 | 2003-06-30 | Pfizer Prod Inc | Sulfamoylheteroarylpyrazolforbindelser som anti-inflammatoriske/analgetiske midler |
CZ20033211A3 (cs) | 2001-05-03 | 2004-09-15 | F. Hoffmann-La Roche Ag | Farmaceutická léková forma amorfního nelfinavir mesylátu |
CA2446904A1 (en) | 2001-05-24 | 2003-04-03 | Alexza Molecular Delivery Corporation | Delivery of drug esters through an inhalation route |
RU2316341C2 (ru) | 2001-08-31 | 2008-02-10 | Бристол-Маерс Сквибб Компани | Применение атазанавира в терапии вич-инфекции |
TW200413273A (en) | 2002-11-15 | 2004-08-01 | Wako Pure Chem Ind Ltd | Heavy hydrogenation method of heterocyclic rings |
AU2004273773B2 (en) | 2003-02-21 | 2008-01-24 | Jarrow Formulas, Inc. | Methods for treatment of HIV or malaria using combinations of chloroquine and protease inhibitors |
US20050131017A1 (en) | 2003-12-11 | 2005-06-16 | Degoey David A. | HIV protease inhibiting compounds |
US20050148523A1 (en) | 2003-12-15 | 2005-07-07 | Colonno Richard J. | Method of treating HIV infection in atazanavir-resistant patients using a combination of atazanavir and another protease inhibitor |
US7829720B2 (en) * | 2004-05-04 | 2010-11-09 | Bristol-Myers Squibb Company | Process for preparing atazanavir bisulfate and novel forms |
EP2336138A3 (en) * | 2004-07-06 | 2011-11-16 | Abbott Laboratories | Prodrugs of HIV protease inhibitors |
AU2005292339A1 (en) | 2004-09-29 | 2006-04-13 | Cordis Corporation | Pharmaceutical dosage forms of stable amorphous rapamycin like compounds |
CN101068916A (zh) | 2004-12-03 | 2007-11-07 | 默克公司 | 阿扎那韦用于改良通过ugt1a1代谢的药物的药物动力学的用途 |
CA2624179A1 (en) | 2005-10-06 | 2007-04-12 | Auspex Pharmaceuticals, Inc. | Deuterated inhibitors of gastric h+, k+-atpase with enhanced therapeutic properties |
US7750168B2 (en) | 2006-02-10 | 2010-07-06 | Sigma-Aldrich Co. | Stabilized deuteroborane-tetrahydrofuran complex |
JO2630B1 (en) | 2006-04-13 | 2012-06-17 | نوفارتيس ايه جي | Organic compounds |
WO2008030382A1 (en) | 2006-09-05 | 2008-03-13 | Schering Corporation | Pharmaceutical combinations for lipid management and in the treatment of atherosclerosis and hepatic steatosis |
AU2008267048C1 (en) | 2007-06-12 | 2013-01-17 | Concert Pharmaceuticals, Inc. | Azapeptide derivatives |
US20090076097A1 (en) | 2007-09-14 | 2009-03-19 | Protia, Llc | Deuterium-enriched atazanavir |
WO2010132663A1 (en) | 2009-05-13 | 2010-11-18 | Concert Pharmaceticals, Inc. | Pegylated azapeptide derivatives as hiv protease inhibitors |
-
2008
- 2008-06-12 AU AU2008267048A patent/AU2008267048C1/en not_active Ceased
- 2008-06-12 EP EP08252023A patent/EP2003120B9/en active Active
- 2008-06-12 PT PT08252023T patent/PT2003120E/pt unknown
- 2008-06-12 PL PL08252023T patent/PL2003120T3/pl unknown
- 2008-06-12 AT AT09075359T patent/ATE536343T1/de active
- 2008-06-12 CN CN2008800216013A patent/CN101711237B/zh not_active Expired - Fee Related
- 2008-06-12 CA CA2692028A patent/CA2692028C/en not_active Expired - Fee Related
- 2008-06-12 CN CN2011102869075A patent/CN102424668A/zh active Pending
- 2008-06-12 SI SI200830012T patent/SI2003120T1/sl unknown
- 2008-06-12 MX MX2009013565A patent/MX2009013565A/es active IP Right Grant
- 2008-06-12 AR ARP080102501A patent/AR066972A1/es unknown
- 2008-06-12 RU RU2010100821/04A patent/RU2448958C2/ru not_active IP Right Cessation
- 2008-06-12 JP JP2010512186A patent/JP2010529196A/ja active Pending
- 2008-06-12 WO PCT/US2008/007331 patent/WO2008156632A1/en active Application Filing
- 2008-06-12 TW TW097122018A patent/TW200908970A/zh unknown
- 2008-06-12 US US12/157,712 patent/US20090036357A1/en not_active Abandoned
- 2008-06-12 RS RSP-2010/0034A patent/RS51226B/sr unknown
- 2008-06-12 ES ES08252023T patent/ES2356334T3/es active Active
- 2008-06-12 AT AT08252023T patent/ATE447554T1/de active
- 2008-06-12 BR BRPI0823520-1A patent/BRPI0823520A2/pt not_active IP Right Cessation
- 2008-06-12 KR KR1020107000675A patent/KR101185899B1/ko not_active IP Right Cessation
- 2008-06-12 DE DE602008000255T patent/DE602008000255D1/de active Active
- 2008-06-12 ES ES09075359T patent/ES2395137T3/es active Active
- 2008-06-12 EP EP11155667A patent/EP2322509B1/en active Active
- 2008-06-12 KR KR1020127003399A patent/KR20120029480A/ko not_active Application Discontinuation
- 2008-06-12 DK DK08252023.0T patent/DK2003120T3/da active
- 2008-06-12 ES ES11155667T patent/ES2394952T3/es active Active
- 2008-06-12 BR BRPI0813911-3A patent/BRPI0813911A2/pt not_active IP Right Cessation
- 2008-06-12 EP EP09075359A patent/EP2116532B1/en active Active
-
2009
- 2009-06-17 HK HK09105433.5A patent/HK1127345A1/xx not_active IP Right Cessation
- 2009-06-17 HK HK10104316.7A patent/HK1136576A1/xx not_active IP Right Cessation
- 2009-12-11 CO CO09141805A patent/CO6241121A2/es not_active Application Discontinuation
- 2009-12-18 ZA ZA2009/09079A patent/ZA200909079B/en unknown
-
2010
- 2010-02-03 CY CY20101100099T patent/CY1109766T1/el unknown
- 2010-02-03 HR HR20100065T patent/HRP20100065T1/hr unknown
- 2010-04-06 US US12/755,184 patent/US8158805B2/en active Active
-
2012
- 2012-01-19 RU RU2012101881/04A patent/RU2012101881A/ru not_active Application Discontinuation
- 2012-03-02 US US13/411,089 patent/US8258309B2/en active Active
- 2012-08-27 US US13/595,511 patent/US20130041156A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HRP20100065T1 (hr) | Derivati azapeptida kao inhibitori hiv proteaze | |
AU2021221855B2 (en) | Therapeutic compounds useful for the prophylactic or therapeutic treatment of an HIV virus infection | |
JP7330312B2 (ja) | Hivを治療するためのトール様受容体の調節因子 | |
EP3752495B1 (en) | Pyridine derivatives and their use for treating hiv infection | |
AU2018317304B2 (en) | Choline salt forms of an HIV capsid inhibitor | |
HRP20191957T1 (hr) | Policiklični-karbamoilpiridonski spojevi i njihova farmaceutska upotreba | |
ES2797900T3 (es) | Compuestos y combinaciones para el tratamiento del VIH | |
NO20073813L (no) | Kladribinregime for behandling av multippel sklerose | |
WO2022081973A1 (en) | Phospholipid compounds and uses thereof | |
NZ791323A (en) | Therapeutic compounds useful for the prophylactic or therapeutic treatment of an HIV virus infection | |
Deodhe et al. | A REVIEW ON ESTIMATION OF EMTRICITABINE AND TENOFOVIR DISOPROXIL FUMARATE IN BULK AND IN PHARMACEUTICAL DOSAGE FORM | |
NZ791314A (en) | Therapeutic compounds useful for the prophylactic or therapeutic treatment of an HIV virus infection | |
EP2780007A1 (en) | Apricitabine and pi combination therapy |